<DOC>
	<DOCNO>NCT00520845</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzyme need cell growth . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving celecoxib together docetaxel pemetrexed may kill tumor cell . PURPOSE : This phase II trial study well celecoxib give together docetaxel pemetrexed work treat patient advanced recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Celecoxib Docetaxel Pemetrexed Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy celecoxib administer standard chemotherapy comprise docetaxel pemetrexed disodium patient advance , recurrent non-small cell lung cancer ( NSCLC ) exhibit cyclooxygenase ( COX ) dependence . Secondary - To determine overall response rate time progression patient COX-dependent recurrent NSCLC treat celecoxib docetaxel pemetrexed disodium . - To determine effect celecoxib urinary metabolite PGE_2 , PGI_2 , thromboxane patient COX-dependent recurrent NSCLC . - To correlate change urinary PGE-M survival intratumoral expression COX-2 , mPGES , 15-PGDH assessed IHC . OUTLINE : Patients prior taxane exposure receive docetaxel IV 1 hour day 1 ; patient prior taxane exposure docetaxel treatment contraindicate receive pemetrexed disodium IV 10 minute day 1 . Treatment docetaxel pemetrexed disodium repeat every 3 week 6 course absence disease progression unacceptable toxicity . All patient receive oral celecoxib twice daily begin 5-7 day prior first docetaxel pemetrexed disodium infusion continue 1 year absence disease progression unacceptable toxicity . Patients undergo blood urine sample collection baseline periodically study biomarker correlative study . Urine sample assess PGE-M level . Blood sample analyze serum celecoxib level , VEGF , endostatin , cytokine assay . After complete last dose celecoxib , patient follow 4-6 week every 3 month thereafter 2 year study entry .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Eligibility Criteria : Cytologically histologically confirm `` COX dependent '' nonsmall cell lung cancer . COX dependency define change urinary PGEM level follow `` runin '' phase celecoxib . Previous treatment ≤2 different chemotherapy regimens one must platinumbased ( cisplatin carboplatin ) chemotherapy . Age ≥18 year ECOG PS 0 , 1 2 . Measurable evaluable disease . At least 3 week post major surgery , chemotherapy radiotherapy &amp; recovered toxicity . Expected survival least 2 month . CNS metastases permit provided patient adequately recover radiotherapy include stereotactic therapy ) surgery . Adequate renal function : serum creatinine ≤1.8 mg/dl &amp; /or CrCl &gt; 50 cc/min Eligibility According Liver Function : AST : &lt; /= 1.5 ULNDocetaxel ; &lt; /= 2.5 ULNPemetrexed ( Liver parameter use pemetrexed absence prove radiographically suspect liver metastasis . ) ; &lt; /= 5.0 ULNPemetrexed ( Liver parameter use pemetrexed presence prove radiographically suspect liver metastasis . ) Alk Phosphatase : &lt; /= 2.5 ULNDocetaxel ; &lt; /= 2.5 ULNPemetrexed ( Liver parameter use pemetrexed absence prove radiographically suspect liver metastasis . ) ; &lt; /= 5.0 ULNPemetrexed ( Liver parameter use pemetrexed presence prove radiographically suspect liver metastasis . ) Total Bilirubin : &lt; /= 1.5 ULNDocetaxel ; &lt; /= 1.5 ULNPemetrexed ( Liver parameter use pemetrexed absence prove radiographically suspect liver metastasis . ) ; &lt; /= 2.5 ULNPemetrexed ( Liver parameter use pemetrexed presence prove radiographically suspect liver metastasis . ) Adequate hematologic function : ANC≥1500/mm3 &amp; platelet ≥100,000/mm3 Female patient pregnant must use contraception childbearing age Lactating woman exclude . Peripheral neuropathy must CTC grade ≤2 Patients must currently nonsteroidal antiinflammatory agent COX2 inhibitor ( Must least ≤7 day ) Written inform consent . More two prior chemotherapy regimens recurrent relapse NSCLC . COX Independent define change urinary PGEM level follow `` runin '' phase celecoxib . Previous treatment docetaxel pemetrexed History great grade 2 allergic reaction celecoxib nonsteroid antiinflammatory agent include aspirin , ibuprofen , indomethacin . History allergy compound contain boron mannitol . History allergy sulfonamide . Concomitant use Warfarin , low dose Coumadin allow port prophylaxis Recent ( past 4 week ) coronary artery bypass graft ( CABG ) surgery . Inadequate organ function : Serum creatinine ≥1.8 mg/dl calculate CrCl &lt; 45 cc/min . AST &gt; 1.5 upper limit normal ( ULN ) ; alkaline phosphatase &gt; 2.5 ULN ; &amp; bilirubin &gt; 1.5 ULN ANC &lt; 1500/mm3 &amp; platelet &lt; 100,000/mm3 Active pregnancy inability unwillingness employ appropriate contraception . Small cell carcinoma histology . Prior malignancy within 5 year diagnosis NSCLC . Exceptions include basal cell nonmetastatic squamous cell carcinoma skin , cervical carcinoma situ FIGO stage I cervical carcinoma , cancer history consider clinically significant principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>